These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21352754)

  • 41. Antiviral treatment for the control of pandemic influenza: some logistical constraints.
    Arinaminpathy N; McLean AR
    J R Soc Interface; 2008 May; 5(22):545-53. PubMed ID: 17725972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimation of optimal antiviral stockpile for a novel influenza pandemic.
    Kim S; Bin Seo Y; Lee J; Kim YS; Jung E
    J Infect Public Health; 2022 Jul; 15(7):720-725. PubMed ID: 35667304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescribing in Alberta's influenza assessment centres.
    Mageau A; Nijssen-Jordan C; Redfern L; Kathol B; Langlois T
    Can Nurse; 2012 Sep; 108(7):26-9. PubMed ID: 23094502
    [No Abstract]   [Full Text] [Related]  

  • 44. Local public health responses to the threat of pandemic flu: equitable protection and communities at disproportionate risk.
    Troutman A; Marshall N
    J Health Care Poor Underserved; 2011 Aug; 22(3 Suppl):43-7. PubMed ID: 21857137
    [No Abstract]   [Full Text] [Related]  

  • 45. Strategies for mitigating an influenza pandemic.
    Ferguson NM; Cummings DA; Fraser C; Cajka JC; Cooley PC; Burke DS
    Nature; 2006 Jul; 442(7101):448-52. PubMed ID: 16642006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influenza. Dueling reviews for controversial flu drug.
    Enserink M
    Science; 2013 Jun; 340(6140):1508-9. PubMed ID: 23812692
    [No Abstract]   [Full Text] [Related]  

  • 47. [The Report of 83(rd) JSOH Conference and a Proposal of Pandemic Flu Preparedness & Response Plan for Businesses and Employers, "Suggested Strategy for Management of Antiviral Drugs"].
    Suzuki H; Wada K; Koga T; Nakamura H; Okada A; Suzuki H; Honda S; Nakano A
    Sangyo Eiseigaku Zasshi; 2011; 53(2):39-43. PubMed ID: 21228509
    [No Abstract]   [Full Text] [Related]  

  • 48. Can antiviral drugs contain pandemic influenza transmission?
    Becker NG; Wang D
    PLoS One; 2011 Mar; 6(3):e17764. PubMed ID: 21464934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antivirals, pandemic planning, and failure to heed calls for trial data.
    Heneghan C; Goldacre B
    BMJ; 2015 Oct; 351():h5635. PubMed ID: 26492895
    [No Abstract]   [Full Text] [Related]  

  • 50. Emergence of drug resistance: implications for antiviral control of pandemic influenza.
    Alexander ME; Bowman CS; Feng Z; Gardam M; Moghadas SM; Röst G; Wu J; Yan P
    Proc Biol Sci; 2007 Jul; 274(1619):1675-84. PubMed ID: 17507331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.
    Hollingsworth TD; Klinkenberg D; Heesterbeek H; Anderson RM
    PLoS Comput Biol; 2011 Feb; 7(2):e1001076. PubMed ID: 21347316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.
    Kelso JK; Halder N; Postma MJ; Milne GJ
    BMC Public Health; 2013 Mar; 13():211. PubMed ID: 23496898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Research into transmissibility of influenza A H5N1: a practical response to the controversy.
    Fedson DS; Opal SM
    Lancet Infect Dis; 2012 May; 12(5):364-5. PubMed ID: 22541628
    [No Abstract]   [Full Text] [Related]  

  • 54. Epidemiological consequences of household-based antiviral prophylaxis for pandemic influenza.
    Black AJ; House T; Keeling MJ; Ross JV
    J R Soc Interface; 2013 Apr; 10(81):20121019. PubMed ID: 23389899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of pandemic influenza preparedness: what's missing?
    Drake TL; Chalabi Z; Coker R
    Bull World Health Organ; 2012 Dec; 90(12):940-1. PubMed ID: 23284200
    [No Abstract]   [Full Text] [Related]  

  • 56. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.
    Handel A; Longini IM; Antia R
    Epidemics; 2009 Sep; 1(3):185-95. PubMed ID: 20161493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions.
    Duerr HP; Brockmann SO; Piechotowski I; Schwehm M; Eichner M
    BMC Infect Dis; 2007 Jul; 7():76. PubMed ID: 17629919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Timely Antiviral Administration During an Influenza Pandemic: Key Components.
    Koonin LM; Patel A
    Am J Public Health; 2018 Sep; 108(S3):S215-S220. PubMed ID: 30192657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choice of Antiviral Allocation Scheme for Pandemic Influenza Depends on Strain Transmissibility, Delivery Delay and Stockpile Size.
    Lydeamore M; Bean N; Black AJ; Ross JV
    Bull Math Biol; 2016 Feb; 78(2):293-321. PubMed ID: 26846916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.
    Carrasco LR; Lee VJ; Chen MI; Matchar DB; Thompson JP; Cook AR
    J R Soc Interface; 2011 Sep; 8(62):1307-13. PubMed ID: 21296791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.